News & Views

  • Collaboration to Explore Acquired Resistance to Targeted Therapies
    Jean-Gabriel Judde

Collaboration to Explore Acquired Resistance to Targeted Therapies

May 15 2019 Read 271 Times

Preclinical research services company XenTech SAS, is collaborating with Gustave Roussy, a leading European cancer centre, on the development of tumour explant models from patients who developed acquired resistance to targeted therapies following initial response. These PDX models will be used in Gustave Roussy’s oncology R&D programs, as well as being added to XenTech’s existing PDX platform for translational oncology research projects for academic and industry customers.
Patients with tumours that harbour specific driver molecular alterations benefit from targeted therapies, but responses are generally short-lived due to the emergence of adaptive/secondary resistance. Between 2015 and 2020 the MATCH-R trial led by Gustave Roussy (NCT02517892) will have enrolled 600 patients treated with targeted therapies. Biopsies will be used to generate PDX models, obtained from 300 patients who have developed resistance following initial response. The MATCH-R PDX platform will be regularly upgraded with new models, providing a unique resource in unravelling the mechanisms involved in acquired resistance to targeted therapies and testing novel therapeutic strategies to circumvent or delay the emergence of resistance.
“We are delighted to collaborate with Gustave Roussy on this unique and ambitious program,” said Jean-Gabriel Judde, CSO and president of XenTech. “These new models will expand XenTech’s bank of PDX models with focus on the advanced drug-resistant setting. The MATCH-R PDX platform will enable a better understanding of acquired resistance to last-generation targeted therapies, providing clinically relevant models to perform preclinical POC studies, translating into increased patient survival. Full clinical and molecular annotation will enable model selection for testing innovative therapies, investigating new and existing pathways and identifying biomarkers.”
“Understanding the mechanisms of acquired resistance to novel targeting agents is crucial in providing optimal care to cancer patients,” said Benjamin Besse, head of the department of medical oncology at Gustave Roussy and principal investigator of the MATCH-R clinical trial. “This strategic collaboration with XenTech, a renowned expert in PDX development and in vivo pharmacological studies, is a major asset for Gustave Roussy’s precision medicine program. There is no doubt that these clinically relevant models will speed-up the development of novel therapeutic agents leading to extended clinical benefit for metastatic cancer patients.”

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment

Digital Edition

Lab Asia August 2019

August 2019

In this Issue Articles Mass Spectrometry & Spectroscopy 67th ASMS Conference on Mass Spectrometry and Allied Topics Chromatography Using Gas Chromatography for measuring atmo...

View all digital editions


ACS National Meeting & Expo, Fall 2019

Aug 25 2019 San Diego, CA, USA

Microscopy Conference 2019

Sep 01 2019 Berlin, Germany

BMSS Annual Meeting

Sep 03 2019 Manchester, UK

JASIS 2019

Sep 04 2019 Chiba City, Japan

ICMGP 2019

Sep 08 2019 Krakow, Poland

View all events